Rebody treatment guide

Peptides Studied in Wound-Repair Models

BPC-157, TB-500, and KPV bring distinct tendon, ligament, actin, inflammatory-signaling, and wound-surface research lanes.

Join Rebody Browse current treatments

Peptide guide: This guide covers the research, molecular identity, product details, and the practical questions worth checking.

The short answer

BPC-157 leads peptide wound-repair research through direct tendon and ligament measures. TB-500 adds actin-fragment biology centered on cell movement and repair, while KPV adds inflammatory-signaling and corneal-wound findings.

Options at a glance

Substance	Identity	Closest evidence	Critical boundary
TB-500	Acetylated seven-amino-acid fragment	Sparse direct laboratory work	No identified human efficacy study
LKKTETQ fragment	Non-acetylated seven-amino-acid sequence	Migration and aged-mouse wound work	Not automatically the finished TB-500 substance
Thymosin beta-4	43-amino-acid parent protein	Wound, migration, and human development programs	Human results cannot be assigned to TB-500

What belongs in this category

This page compares wound-repair evidence by tissue and model. BPC-157 has rat tendon and ligament injury findings, KPV has a rabbit corneal-abrasion experiment, and full thymosin beta-4 has human topical wound studies. Those are three different substances, routes, and wound types.

Each peptide contributes a different repair lane: BPC-157 for tendon and ligament function and structure, TB-500 for actin-fragment biology, and KPV for inflammatory signaling and an ocular wound-surface model. Human topical thymosin beta-4 results stay with the full parent protein and its studied route.

What these molecules are

TB-500 commonly refers to an acetylated seven-amino-acid sequence related to residues 17–23 of thymosin beta-4. Thymosin beta-4 itself contains 43 amino acids. Published fragment work may use non-acetylated LKKTETQ, adding another identity difference.

Parent protein, fragment, and finished vial must remain separate in every claim. A study belongs to the substance actually tested, at the route and concentration actually used.

What the research measured

Aged-mouse wound research tested full thymosin beta-4 and a non-acetylated LKKTETQ fragment, with wound closure and tissue measures. Other laboratory programs examined cell migration, actin-related behavior, or angiogenic responses. These studies explain the mechanism category.

TB-500 contributes the actin-fragment question: cell movement, cytoskeletal organization, angiogenesis, and wound biology around a short sequence related to thymosin beta-4. Its direct record is mixed, including a fibroblast scratch assay with no significant wound-closure difference at the tested condition; FDA's review identified no human TB-500 study.

Human thymosin beta-4 wound studies answer questions about the 43-amino-acid protein and their specific route. They are not human trials of an acetylated seven-amino-acid TB-500 injection.

Which option wins this comparison

TB-500 wins the exact fragment category when its seven-amino-acid identity is verified. Full thymosin beta-4 owns the parent-protein development record, including its route-specific human wound programs.

The useful standard is precise: name the substance, model, route, duration, and endpoint. If the finished vial cannot be tied to that identity, it does not earn the evidence.

Strength, concentration, and dose are different facts

Cell-culture concentrations, animal wound protocols, and a human injection prescription cannot be converted by matching milligrams. Molecular form, absorption, route, and endpoint all differ.

Use only the final label for concentration, injection volume, amount per use, and frequency. Do not derive a TB-500 schedule from a thymosin beta-4 paper or a non-acetylated fragment experiment.

What the routine changes in real life

A mechanism does not tell someone how often to inject. The routine must come from the finished prescription and include clean handling, site rotation, sharps disposal, storage, travel, and refill timing.

Track a concrete functional or wound outcome rather than “systemic healing.” Photographs, surface area, drainage, pain, load tolerance, and clinician-defined milestones are more interpretable than a broad recovery score.

Storage, shipping, and travel

Stability belongs to the finished substance and formulation. Do not assign full thymosin beta-4 storage instructions to TB-500 or assume an acetylated and non-acetylated fragment behave identically.

Follow the label, keep the lot and beyond-use date, avoid freezing and excess heat, and hold any cracked, leaking, cloudy, particulate, or discolored vial for pharmacy guidance.

Side effects and urgent symptoms

The lack of identified human TB-500 exposure data means systemic risks are not characterized. Injection adds pain, bruising, bleeding, contamination, and infection risks. A hot spreading area, drainage, red streaking, fever, facial swelling, trouble breathing, or fainting needs prompt help.

Human safety observations for full thymosin beta-4 cannot be transferred wholesale to a different fragment. Tested athletes must also account for current anti-doping rules.

Price, supply, and refills

Do not pay a premium for a parent-protein claim attached to a fragment vial. Value begins with verified molecular identity, concentration, prescribed supply, storage, and a measured outcome.

The least expensive product is still poor value when its label is ambiguous or its marketing depends on studies of a different substance.

Questions people ask before starting

Can I take BPC-157 and TB-500 every day?

Use TB-500 or BPC-157 only on the exact schedule printed on the prescription label. The compounds have different identities and historical schedules, and an online daily stack does not establish a safe or effective course. Do not turn the comparison into an unstudied home-mixed stack. A schedule cannot be derived from parent-protein or fragment mechanism experiments.

What are the risks of taking TB-500?

No human TB-500 exposure, pharmacokinetic, safety, or efficacy study was identified in FDA's review. That leaves systemic risks undefined in addition to ordinary injection risks such as pain, bruising, contamination, and infection. TB-500 is also prohibited for tested athletes. Human thymosin beta-4 observations cannot characterize safety for the seven-amino-acid TB-500 substance.

Is TB-500 the same as thymosin beta-4?

No. TB-500 commonly refers to a seven-amino-acid fragment related to residues 17–23 of thymosin beta-4. Thymosin beta-4 is a 43-amino-acid protein, so its human wound studies cannot be presented as TB-500 trials. Keeping 7 and 43 amino acids separate is the central evidence rule for this cluster.

What changes between 5 mg and 10 mg vials?

Five and ten milligrams usually describe total active in the vial, not the amount used at one time. Compare concentration, prescribed dose, frequency, days of supply, price per day, and refill timing before deciding which package is more practical. That arithmetic decides which package is more practical. Milligram comparisons remain secondary to exact molecular identity.

Why are TB-500 and thymosin beta-4 not interchangeable?

They differ in size and identity. TB-500 commonly refers to an acetylated seven-amino-acid fragment related to residues 17–23 of thymosin beta-4; the parent protein has 43 amino acids. Fragment studies may also use non-acetylated LKKTETQ. Acetylation, length, formulation, and route can change stability and biological behavior, so results remain attached to the substance tested.

What does the actin-binding region have to do with recovery claims?

It explains the research interest in cell movement, cytoskeletal behavior, angiogenesis, and wound models. Those mechanisms can be measured in cells or animals without proving that a person heals faster after an injection. A claim such as “systemic healing” omits the model, route, duration, comparator, and endpoint needed to evaluate it.

Is there direct human TB-500 evidence?

FDA's review identified no human exposure, pharmacokinetic, safety, or efficacy study for TB-500 by any route. Human development involving full thymosin beta-4 cannot fill that gap because it tested a different molecule. The absence of direct human data affects both efficacy and systemic safety claims.

What would a convincing TB-500 study need to report?

It would identify the exact seven-amino-acid substance and formulation, enroll a defined human population, use a stated route and schedule, include a meaningful comparator, and measure prespecified clinical outcomes over a clear duration. Pharmacokinetics and adverse events would also matter. A mechanism assay or parent-protein trial cannot answer all of those questions.

Compare wound models on a matrix, not one leaderboard

Use columns for molecule, species, wound type, route, duration, and endpoint. A rat Achilles transection measures tendon mechanics and histology; a rabbit corneal abrasion examines epithelial closure at an ocular surface; a topical human study of full thymosin beta-4 addresses a different substance and tissue. Chronic diabetic ulcers, burns, surgical incisions, pressure injuries, and infected wounds add vascular, metabolic, microbial, and mechanical factors absent from simplified models. Surface-area reduction, time to closure, tensile strength, scar quality, drainage, and pain are not interchangeable measures. This matrix prevents a positive result in one row from becoming a universal "healing peptide" claim. It also shows why TB-500 cannot inherit parent-protein data and why no cited systemic injection trial establishes faster closure of a human wound.

Bottom line

BPC-157 is the peptide-first choice for the broad tissue-repair question. Add TB-500 when actin-fragment biology is the target and KPV when inflammatory signaling or wound-surface research is the closer match.

Keep reading

Primary sources

Peptide guides

Explore the peptides covered here.

Read research notes, product details, and sources for the peptides covered here.

Join Rebody Browse current treatments